Physician profile
Delayne A Long
NPI 1326435397
$733.86
in general payments reported to CMS, 2019-2025
14 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $81.99 · 2021: $127 · 2023: $64.50 · 2024: $162 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $106.30 | 2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $93.87 | 2020-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $92.89 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $86.01 | 2021-2025 | |
| Glaxosmithkline, LLC. | $80.02 | 2020-2025 | Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.76 | 2020-2025 | Jardiance |
| Abbvie INC. | $63.25 | 2023-2024 | |
| Amgen INC. | $26.30 | 2021-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $24.90 | 2025 | Trintellix |
| Merck Sharp & Dohme LLC | $21.10 | 2024 | Vaxelis, Vaxneuvance, Gardasil |
| Xeris Pharmaceuticals, INC. | $20.28 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $19.45 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $15.66 | 2025 | |
| Sanofi-Aventis U.S. LLC | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delayne Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.